This ruling removes a material coverage liability for WRB and reinforces the enforceability of capacity exclusions in D&O policies under New Jersey law. However, the dissent and unresolved factual issues on withholding consent to settle suggest some residual litigation risk on remand for Berkley's unreimbursed defense costs.
Price Chart
Executive Summary
The New Jersey Supreme Court ruled that Berkley Insurance Company validly denied coverage to Mist Pharmaceuticals under a D&O policy's capacity exclusion, holding that the claims against Mist Pharmaceuticals solely involved Krivulka's wrongful acts in an uninsured capacity (as a director of Akrimax). The Court affirmed the Appellate Division's reversal of the trial court's $1.75M judgment against Berkley, finding Berkley properly reserved its rights and did not forfeit coverage defenses by withholding consent to settle. This is a clear legal win for Berkley, removing a ~$2.5M liability and confirming that its policy exclusion language is enforceable.
Court Ruling Details
Key Facts
- New Jersey Supreme Court held that Berkley's D&O capacity exclusion unambiguously bars coverage for Mist Pharmaceuticals' claims because all underlying allegations involved Krivulka's wrongful acts as a director/member of uninsured entities (Akrimax, Mist Acquisition, etc.)
- Court found Berkley did not forfeit its right to rely on the capacity exclusion; it repeatedly reserved rights in letters and emails at least 10 times over 5 years
- Court rejected estoppel argument under Griggs v. Bertram, noting Berkley gave timely notice of potential disclaimer unlike the insurer in that case
- Court distinguished Fireman's Fund Insurance Co. v. Security Insurance Co., finding no bad faith or breach because Berkley correctly determined the policy did not cover the claims
- Dissent by Justice Fasciale argued Berkley's conduct estopped it from relying on the exclusion and that the exclusion does not bar all coverage when an insured acts in dual capacities
Financial Impact
Eliminates $1.75M judgment against Berkley plus $796K in legal fees; policy limit exposure of $2M removed
Risk Factors
- Dissent raises possibility of remand for factual determinations on whether Berkley unreasonably withheld consent to settle
- Mist Pharmaceuticals may seek certiorari to U.S. Supreme Court (though unlikely given state-law grounding)
- Claim of $300M settlement exposure in underlying case could resurface via other theories if coverage ruling is overturned on rehearing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-fbhddsn5-WRB |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 26, 2026 13w ago | 8-K | $71.01 $68.17 | ▼ −4.00% | ▼ −8.39% | $68.98 (−2.86%) |
Jun 11, 2026 16w ago | Institutional Cluster | $68.27 $69.77 | ▲ +2.20% | ▼ −1.07% | $68.98 (+1.04%) |
Jun 10, 2026 16w ago | 8-K | $15.34 awaiting T+60 | awaiting T+60 | — | $68.98 (+349.67%) |
May 11, 2026 20w ago | Court Ruling | $66.41 $71.99 | ▲ +8.41% | ▲ +4.28% | $68.98 (+3.87%) |
Apr 21, 2026 23w ago | 8-K | — | awaiting T+60 | — | — |
Feb 20, 2026 32w ago | Court Ruling | $71.08 $68.76 | ▼ −3.26% | ▼ −10.40% | $68.98 (−2.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access